Adenovirus-vectored African Swine Fever Virus antigen cocktails are immunogenic but not protective against intranasal challenge with Georgia 2007/1 isolate

Lokhandwala, Shehnaz; Petrovan, Vlad; Popescu, L; Sangewar, Neha; Elijah, C. Grace; Stoian, Ana M. M.; Olcha, Matthew; Ennen, Lindsey; Bray, Jocelyn; Bishop, Richard P.; Waghela, Suryakant D.; Sheahan, Maureen A.; Rowland, Raymond R. R.; Mwangi, Waithaka

doi:10.1016/j.vetmic.2019.06.006

Cited by 57 publications

(86 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This work has been more recently confirmed by identifying CD2v and the ASFV lectin as key protective antigens [83], which could be useful to serotype ASFV [67]. As described for p32, p54 and p72, some experimental vaccine formulations containing CD2v have failed at inducing solid protection, perhaps reflecting antigenic and pathogenic differences between the ASFV strains used or in the vaccine formulations per se [37,38,78,81,84].…”

Section: The Yin and The Yang Of Asfv-specific Antibodiesmentioning

confidence: 78%

“…In fact, antigenicity and protection do not concur and, on occasions, and an inverse correlation has even been demonstrated. This effect has been described upon natural and experimental ASFV infection with LAVs and also after immunization with inactivated and subunit vaccine formulations [17,[36][37][38]81].…”

Section: The Yin and The Yang Of Asfv-specific Antibodiesmentioning

confidence: 86%

“…Immunization with different cocktails of recombinant adenoviruses allowed the confirmation of the immunogenicity of B602L, K205R-A104R, CP530R, CP2475L and the extracellular domain of EP402R, identifying for the first time A151R and B119L as good antibody inducers, albeit none of the cocktails induced significant protection against Georgia2007/1 [71,74,81]. Immunization with recombinant adenoviruses encoding: p32, p54, pp62, p72, and p37 and p150 (mature proteins processed from the pp220 polyprotein) seemed to afford some protection depending on the adjuvant used, while other vaccine formulations exacerbated the disease [81].…”

Section: The Yin and The Yang Of Asfv-specific Antibodiesmentioning

confidence: 99%

“…Interestingly, immunization with adenoviruses encoding the structural proteins: p32, p54, pp62, p72 and pp220 in the presence of the ZTS-01 adjuvant induced lower antibody responses and slightly better protection (non-statistically significant), than with the BioMize Table 3 ASFV-specific T-cell determinants, indicating those described to be recognized by PBMCs from pigs recovered from ASFV infection (antigenic) and those inducing T-cell responses after in vivo immunization (immunogenic) (Continued) 0226 adjuvant, reflecting most probably the differential innate immune responses induced by each adjuvant [81]. On the other hand, immunization with cocktails up to 47 antigens in a DNA priming and vaccinia virus-boosting regime, allowed the identification of novel T-cell antigens.…”

Section: The Yin and The Yang Of Asfv-specific Antibodiesmentioning

confidence: 99%

See 3 more Smart Citations

African swine fever vaccines: a promising work still in progress

2020

View full text Add to dashboard Cite

African swine fever (ASF), a disease of obligatory declaration to the World Organization for Animal Health (OIE), has contributed to poverty and underdevelopment of affected areas. The presence of ASF has been historically neglected in Africa, contributing to its uncontrolled expansion and favouring its spread to continental Europe on at least three occasions, the last one in 2007 through the Republic of Georgia. Since then, African swine fever virus (ASFV) has spread to neighbouring countries, reaching the European Union in 2014, China in the summer of 2018 and spreading through Southeast Asia becoming a global problem. Lack of available vaccines against ASF makes its control even more difficult, representing today the number one threat for the swine industry worldwide and negatively affecting the global commerce equilibrium. Main body: In this review, we intend to put in perspective the reality of ASF vaccination today, taking into account that investment into ASF vaccine development has been traditionally unattractive, overall since ASF-free areas with large swine industries applied a non-vaccination policy for diseases listed by the OIE. The dramatic situation suffered in Asia and the increasing threat that ASF represents for wealthy countries with large swine industries, has dramatically changed the perspective that both private and public bodies have about ASF vaccinology, although this is controversial. The feasibility of modifying the ASFV genome has led to safe and efficacious experimental recombinant live attenuated viruses (LAVs). The main challenge today will be confirming the safety and efficacy of these technologies in the field, accelerating transfer to the industry for official registration and commercialization. The complexity of ASFV, together with the lack of knowledge about the mechanisms involved in protection and the specific antigens involved in it, requires further investment in research and development. Although far from the efficacy achieved by LAVs, subunit vaccines are the optimal choice for the future. If the world can wait for them or not is a contentious issue. Conclusion: Despite their inherent disadvantages, LAVs will be the first technology to reach the market, while subunit vaccines will need much further research to become a successful commercial reality.

show abstract

Section: The Yin and The Yang Of Asfv-specific Antibodiesmentioning

confidence: 78%

Section: The Yin and The Yang Of Asfv-specific Antibodiesmentioning

confidence: 86%

Section: The Yin and The Yang Of Asfv-specific Antibodiesmentioning

confidence: 99%

Section: The Yin and The Yang Of Asfv-specific Antibodiesmentioning

confidence: 99%

See 2 more Smart Citations

African swine fever vaccines: a promising work still in progress

2020

View full text Add to dashboard Cite

show abstract

“…In contrast, the antibody response induced by ZTS-01 preparation was even weaker, paradoxically, 5/9 vaccinated pigs could resist the attack of homologous virulent strains, and survivors showed mild clinical symptoms and no viremia (non-statistical significance). The contradictory results in this study show that immune-induced antibody responses are not necessarily proportional to protective immunity, highlighting the complexity of the role of antibody responses in anti-ASFV, and also reflecting that different adjuvants may induce different innate immune responses, which require further study and evaluation of the efficacy of neoantigens formulated in appropriate adjuvants [ 99 ]. Moreover, Murgia et al discovered that the strategy enhanced with natural attenuated strain OURT88/3 could broaden the recognition of ASFV epitopes, but its protective efficacy needs further verification [ 100 ].…”

Section: Current State Of Asf Vaccine Developmentmentioning

confidence: 99%

Current State of Global African Swine Fever Vaccine Development under the Prevalence and Transmission of ASF in China

Liu

Wang

et al. 2020

Vaccines

View full text Add to dashboard Cite

African swine fever (ASF) is a highly lethal contagious disease of swine caused by African swine fever virus (ASFV). At present, it is listed as a notifiable disease reported to the World Organization for Animal Health (OIE) and a class one animal disease ruled by Chinese government. ASF has brought significant economic losses to the pig industry since its outbreak in China in August 2018. In this review, we recapitulated the epidemic situation of ASF in China as of July 2020 and analyzed the influencing factors during its transmission. Since the situation facing the prevention, control, and eradication of ASF in China is not optimistic, safe and effective vaccines are urgently needed. In light of the continuous development of ASF vaccines in the world, the current scenarios and evolving trends of ASF vaccines are emphatically analyzed in the latter part of the review. The latest research outcomes showed that attempts on ASF gene-deleted vaccines and virus-vectored vaccines have proven to provide complete homologous protection with promising efficacy. Moreover, gaps and future research directions of ASF vaccine are also discussed.

show abstract